Outcomes, Prognostic Factors and Salvage Treatment for Recurrent Chordoma After Pencil Beam Scanning Proton Therapy at the Paul Scherrer Institute

2020 ◽  
Vol 32 (8) ◽  
pp. 537-544
Author(s):  
J. Beer ◽  
M. Kountouri ◽  
A.J. Kole ◽  
F.R. Murray ◽  
D. Leiser ◽  
...  
2015 ◽  
Vol 18 (2) ◽  
pp. 236-243 ◽  
Author(s):  
Damien C. Weber ◽  
Shahed Badiyan ◽  
Robert Malyapa ◽  
Francesca Albertini ◽  
Alessandra Bolsi ◽  
...  

2015 ◽  
Vol 17 (suppl 8) ◽  
pp. viii3.4-viii3 ◽  
Author(s):  
Damien Charles Weber ◽  
Shahed Badiyan ◽  
Tony Lomax ◽  
Robert Malyapa ◽  
Alessandra Bolsi ◽  
...  

2016 ◽  
Vol 18 (suppl 3) ◽  
pp. iii19.5-iii20
Author(s):  
Damien Charles Weber ◽  
Alessia Pica ◽  
Carmen Teske ◽  
Ulrike Kliebsch ◽  
Ralf Schneider ◽  
...  

2015 ◽  
Vol 63 (10) ◽  
pp. 1731-1736 ◽  
Author(s):  
Damien C. Weber ◽  
Carmen Ares ◽  
Francesca Albertini ◽  
Martina Frei-Welte ◽  
Felix K. Niggli ◽  
...  

2020 ◽  
Vol 32 (6) ◽  
pp. 921-930
Author(s):  
Fritz R. Murray ◽  
James W. Snider ◽  
Ralf A. Schneider ◽  
Marc Walser ◽  
Alessandra Bolsi ◽  
...  

OBJECTIVEThe aim of this paper was to evaluate the prognostic factors in surgical and adjuvant care for spinal chordomas and chondrosarcomas after surgery followed by high-dose pencil-beam scanning proton therapy (PBS-PT).METHODSFrom 1997 to 2016, 155 patients (61 female patients; median age 55 years) with spinal (cervical, n = 61; thoracic, n = 29; lumbar, n = 13; sacral, n = 46; pelvic, n = 6) classic chordomas (n = 116) and chondrosarcomas (n = 39; most were low grade) were treated with maximal safe resection followed by PBS-PT (median dose prescribed: 74 Gy [relative biological effectiveness], range 48.6–77 Gy). The majority of patients (n = 153, 98.7%) had undergone at least 1 resection prior to PBS-PT (median 1, range 0–5; biopsy only, n = 2). Fewer than half (45.1%) of the surgeries were rated as gross-total resections (GTRs) prior to PBS-PT. Surgical stabilization (SS) was present in 39% of all patients (n = 60). Ninety-one patients (59%) presented with macroscopic tumor at the start of PBS-PT. The median follow-up duration was 64.7 months (range 12.2–204.8 months).RESULTSThe 5-year local tumor control, disease-free survival (DFS), and overall survival were 64.9% (95% CI 56.3%–73.5%), 59.4% (95% CI 50.6%–68.2%), and 77.9% (95% CI 70.6%–85.2%), respectively. In total, 63 patients (40.6%) experienced failure during the follow-up period: local only in 32 (20.6%), distal only in 7 (4.5%), local + distal in 19 (12.3%), surgical pathway failure (SPF) only in 2 (1.3%), local + SPF in 2 (1.3%), and distal + SPF in 1 (< 1%). Univariate analysis identified gross residual disease, the presence of SS, and treatment era prior to 2008 as highly significant for worse outcome, with all 3 remaining significant on multivariate analysis. The type of surgery (GTR or subtotal resection/biopsy) and whether GTR was achieved by en bloc or curettage did not show a significant prognostic effect. Surgical complications prior to PBS-PT were present in 42.5% of all surgically treated patients and were seen more commonly in patients with multiple surgical interventions (p = 0.005) and those operated on with the intent of en bloc resection (p = 0.006).CONCLUSIONSThe extent of resection and metallic stabilization substantially influenced clinical outcomes for patients with spinal chordoma or chondrosarcoma despite high-dose adjuvant PBS-PT. Optimal upfront surgical management of these tumors continues to include GTR, as possible, with prompt adjuvant proton therapy.


2021 ◽  
Author(s):  
Konrad P. Nesteruk ◽  
Michele Togno ◽  
Martin Grossmann ◽  
Anthony J. Lomax ◽  
Damien C. Weber ◽  
...  

2021 ◽  
Vol 82 ◽  
pp. 134-143
Author(s):  
M. De Saint-Hubert ◽  
C. De Angelis ◽  
Ž. Knežević ◽  
B. Michalec ◽  
B. Reniers ◽  
...  

2015 ◽  
Vol 16 (6) ◽  
pp. 281-292 ◽  
Author(s):  
Liyong Lin ◽  
Minglei Kang ◽  
Sheng Huang ◽  
Rulon Mayer ◽  
Andrew Thomas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document